Rituximab-based therapy in infection-associated severe crescentic proliferative glomerulonephritis with monoclonal immunoglobulin deposition

Read full text Summarise with VIRAT
Authors: Paola A Richiez Nieves, William L. Clapp, Chintan Vimalkumar Shah
Cited by: 0
References: 5

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

To the Editor, Javaugue et al. recently showed that over 90% of IgG3 proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) cases lack a monoclonal etiology, using their highly sensitive immunoglobulin repertoire sequencing (RACE-RepSeq) of bone marrow (BM) RNA. Many instead likely reflect oligoclonal or polyclonal immune responses to viral or bacterial antigens [1]. We report a young female who developed severe crescentic, oliguric, dialysis-requiring acute kidney injury with IgG3 PGNMID 2 weeks after a flu-like illness, successfully treated with rituximab. A 40-year-old female with no significant medical history except for obesity and preeclampsia (2009 and 2023), who was noted to have elevated blood pressure (150/95 mmHg), hematuria, and proteinuria on urine analysis during an emergency room visit in August 2024, during a flu-like illness (fever 102.9 °F), but no further workup was pursued. Serum creatinine (S. Cr) was 0.9 mg/dl (79.6 µmol/l), and blood pressure was normalized on follow-up home measurements. She developed another flu-like illness (fever 101.0 °F; COVID-19, influenza A and B were negative) in March 2025. Two weeks later, the patient presented to the emergency room with new onset elevated blood pressure (213/113 mmHg) and acute kidney injury, with S. Cr 4.1 mg/dl (362.4 µmol/l), rising to 13 mg/dl (1149.2 µmol/l) within 10 days, along with oliguria (nadir urine output 200 ml/day). Kidney biopsy findings on light microscopy showed 76% cellular crescents (19 of 25 glomeruli), with virtually all glomeruli demonstrating a membranoproliferative pattern (endocapillary hypercellularity and capillary wall double contouring), 20% interstitial fibrosis, and focal acute tubular injury, with minimal inflammatory cells in the interstitium. Immunofluorescence was positive for IgG (3+), C3 (3+), C1q (3+), kappa light chain (trace), and lambda light chain (4+) with IgG3 subclass (3–4+), and electron microscopy showed mesangial and subendothelial electron-dense deposits (Supplementary Fig. S1) with overall findings consistent with PGNMID. Despite thorough testing, no pathological clone was found (Fig. 1A). She began hemodialysis, high-dose steroids, and received rituximab 1 g before discharge to outpatient dialysis. Two months after rituximab, urine output increased to 2600 ml/day, combined urea and creatinine clearance rose to 15 ml/min, and dialysis was discontinued. Another dose of rituximab 1 g was given at this time, and by 6 months, S. Cr improved to 1.98 mg/dl, with random urine protein/creatinine of 0.5 and urine microscopy showing 3 red blood cells/hpf. Peripheral blood CD20 cell count remained at 0 cells/µl, measured 2 days after the first dose, prior to discharge, and monthly thereafter up to 8 months from the first dose of rituximab (Fig. 1B). (A) Workup at the time of kidney biopsy. (B) Clinical course. FLC, free light chain; κ, kappa; λ, lambda; SPEP, serum protein electrophoresis; SIF, serum immunofixation; MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-flight mass spectrometry; CT scan, computerized tomography scan. a. Number of events acquired: 4544 236; lower limit of detection 0.0011%; antigens examined: cKappa, cLambda, CD19, CD27, CD38, CD45, CD56, CD81, CD117, cVS38c; overall plasma cell kappa:lambda ratio: ∼1:1. Note: high-sensitivity flow cytometry achieves ∼10⁻⁵ detection (1 clonal plasma cell per 100 000 cells). We previously reported pregnancy-associated PGNMID [3]. However, subsequent normalization of blood pressure and kidney function makes pregnancy an unlikely primary cause of the current presentation in this case. Instead, a flu-like illness raises the possibility of triggering an oligoclonal or polyclonal response secondary to small B-cell clone stimulation from viral antigen, leading to infection-associated PGNMID, which may or may not represent a “second-hit” phenomenon. This is consistent with the findings in the multicenter series reported by Javaugue et al., in which infections within 1 year before diagnosis were observed in 7/42 patients (17%), all with IgG3 PGNMID, and BM examination showed overrepresentation of the IgG1 isotype in immunoglobulin repertoires compared to controls, suggesting an adaptive immune response against viral or bacterial protein antigens [1]. Although steroids may temporarily help control inflammation in cases of PGNMID, steroid monotherapy can worsen proteinuria and yield an incomplete response, as noted in previous cases [3,4], and clone-directed therapy remains the treatment standard [5]. However, bridging with steroids may be helpful, especially during rapidly declining renal function, until clone-directed therapy is initiated and its effects are evident. Among non-IgM PGNMID patients without a detectable clone, previous data indicate that some respond only to anti-CD20 B-cell-directed therapy, whereas others respond only to anti-CD38 plasma cell-directed therapy [2–4]. Yet, as of 2025, no data exist on how to prioritize these therapies [4,5]. We previously suggested that age at diagnosis may be helpful [3]. Here, we propose that infection-triggered PGNMID may respond well to anti-CD20 B-cell-directed therapy; however, the risk of relapse remains unknown, given the limited follow-up in our case. Further studies are needed to identify factors that can guide therapy prioritization. Additionally, clinical trials of daratumumab for PGNMID should consider reporting pre-enrollment infection history and offer nonresponders an option for anti-CD20 B-cell-directed therapy. Informed consent was obtained from the patients described in this report. All authors declare that there is no conflict of interest.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Vasculitis and related conditions Systemic Lupus Erythematosus Research

Publication details

Journal / source
Clinical Kidney Journal
Volume
19
Issue
4
Pages
sfag094–sfag094
Publication date
25 March 2026
Language
EN